The field of biomedical research is on the cusp of a transformative era, driven by the convergence of artificial intelligence (AI) and genomics. At the forefront of this revolution is EVO-2, a groundbreaking AI model developed by Arc Institute and NVIDIA. Trained on an unprecedented scale of over 9 trillion DNA base pairs from over 128,000 species across all domains of life, EVO-2 possesses a profound understanding of the genetic code. This deep learning model goes beyond simply analyzing existing genomes; it can generate entirely new genetic sequences, predict the impact of mutations, and even design artificial genomes.

The field of biomedical research is on the cusp of a transformative era, driven by the convergence of artificial intelligence (AI) and genomics. At the forefront of this revolution is EVO-2, a groundbreaking AI model developed by Arc Institute and NVIDIA. Trained on an unprecedented scale of over 9 trillion DNA base pairs from over 128,000 species across all domains of life, EVO-2 possesses a profound understanding of the genetic code. This deep learning model goes beyond simply analyzing existing genomes; it can generate entirely new genetic sequences, predict the impact of mutations, and even design artificial genomes.

Artificial Intelligence (AI) is transforming industries at an unprecedented pace, and genetic engineering is no exception. With AI’s potential to accelerate research, optimize workflows, and unlock insights from complex datasets, organizations in genetic engineering R&D are increasingly looking to adopt AI solutions. But is your company ready to integrate AI into its processes?

In the race to adopt AI technologies, many businesses eagerly embrace public large language models (LLMs) like ChatGPT. While these tools offer impressive capabilities, they also introduce significant risks that companies often overlook.

By Dr. Piru Perampalam, Chief Scientific Officer, and Giselle Bagatini, Chief AI Officer, Copoly The fight against cancer is one of the most challenging and critical battles in modern medicine. Despite significant advancements, early cancer detection remains a complex problem due to the disease’s inherent heterogeneity among patients. At Copoly, we believe we are uniquely […]

Cancer is a global health crisis, affecting millions of people every year. Despite advancements in medical research and technology, an alarming statistic persists: approximately 50% of cancers are diagnosed at advanced stages, when treatment options are limited and survival rates are significantly lower. This article explores the implications of late cancer diagnoses, the factors contributing […]